Evidence map›Paper›PMID 35629227›Full record

ArticleJournal of personalized medicine2022

Sustained Hyperglycemia and Its Relationship with the Outcome of Hospitalized Patients with Severe COVID-19: Potential Role of

Jose R Vargas-Rodriguez, José J Valdés Aguayo, Idalia Garza-Veloz, Jacqueline Martinez-Rendon, Maria Del Refugio Rocha Pizaña, Griselda A Cabral-Pacheco, Vladimir Juárez-Alcalá, Margarita L Martinez-Fierro

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Host factors of SARS-CoV-2 in infection, pathogenesis, and long-term effects.Frontiers in cellular and infection microbiology · 2024
    Review
  5. Review
  6. Article
  7. Article
  8. Prognostic performance of the Age, PaOTherapeutic advances in infectious disease
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jose R Vargas-RodriguezMolecular Medicine Laboratory, Unidad Academica de Medicina Humana y C.S, Campus UAZ siglo XXI-L1, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico.ORCID 0000-0002-4585-2982
José J Valdés AguayoMolecular Medicine Laboratory, Unidad Academica de Medicina Humana y C.S, Campus UAZ siglo XXI-L1, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico.ORCID 0000-0003-2822-7277
Idalia Garza-VelozMolecular Medicine Laboratory, Unidad Academica de Medicina Humana y C.S, Campus UAZ siglo XXI-L1, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico.ORCID 0000-0002-6307-1696
Jacqueline Martinez-RendonMolecular Medicine Laboratory, Unidad Academica de Medicina Humana y C.S, Campus UAZ siglo XXI-L1, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico.
Maria Del Refugio Rocha PizañaEscuela de Ingenieria y Ciencias, Tecnologico de Monterrey Campus Puebla, Puebla 72453, Mexico.ORCID 0000-0003-1575-940X
Griselda A Cabral-PachecoMolecular Medicine Laboratory, Unidad Academica de Medicina Humana y C.S, Campus UAZ siglo XXI-L1, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico.
Vladimir Juárez-AlcaláMolecular Medicine Laboratory, Unidad Academica de Medicina Humana y C.S, Campus UAZ siglo XXI-L1, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico.
Margarita L Martinez-FierroMolecular Medicine Laboratory, Unidad Academica de Medicina Humana y C.S, Campus UAZ siglo XXI-L1, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico.ORCID 0000-0003-1478-9068
Universidad Autónoma de Zacatecas "Francisco García Salinas" · MXTecnológico de Monterrey · MX

Funding

Consejo Nacional de Ciencia y Tecnología 314340 (A12 xii. 2020)
6 · The paper itself

Abstract

Chronic hyperglycemia increases the risk of developing severe COVID-19 symptoms, but the related mechanisms are unclear. A mean glucose level upon hospital admission >166 mg/dl correlates positively with acute respiratory distress syndrome in patients with hyperglycemia. The objective of this study was to evaluate the relationship between sustained hyperglycemia and the outcome of hospitalized patients with severe COVID-19. We also evaluated the effect of high glucose concentrations on the expression of angiotensin-converting enzyme 2 (ACE2). We carried out a case-control study with hospitalized patients with severe COVID-19 with and without sustained hyperglycemia. In a second stage, we performed in vitro assays evaluating the effects of high glucose concentrations on ACE2 gene expression. Fifty hospitalized patients with severe COVID-19 were included, of which 28 (56%) died and 22 (44%) recovered. Patients who died due to COVID-19 and COVID-19 survivors had a high prevalence of hyperglycemia (96.4% versus 90.9%), with elevated central glucose upon admission (197.7 mg/dl versus 155.9 mg/dl, p = 0.089) and at discharge (185.2 mg/dl versus 134 mg/dl, p = 0.038). The mean hypoxemia level upon hospital admission was 81% in patients who died due to COVID-19 complications and 88% in patients who survived (p = 0.026); at the time of discharge, hypoxemia levels were also different between the groups (68% versus 92%, p ≤ 0.001). In vitro assays showed that the viability of A549 cells decreased (76.41%) as the glucose concentration increased, and the ACE2 gene was overexpressed 9.91-fold after 72 h (p ≤ 0.001). The relationship between hyperglycemia and COVID-19 in hospitalized patients with COVID-19 plays an important role in COVID-19-related complications and the outcome for these patients. In patients with chronic and/or sustained hyperglycemia, the upregulation of ACE2, and its potential glycation and malfunction, could be related to complications observed in patients with COVID-19.

Indexed as

ACE2COVID-19diabetes mellitushyperglycemiaSARS-CoV-2

Identifiers

PMID35629227
PMCPMC9147379
OpenAlexW4280614157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.